Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.


Choe, S. et al.
Blood Advances (2020)
Abstract

Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant IDH1 (mIDH1) enzyme inhibitor, can restore normal differentiation and results in clinical responses in a subset of patients with mIDH1 relapsed/refractory (R/R) acute myeloid leukemia (AML). We explored mechanisms of ivosidenib resistance in 174 patients with confirmed mIDH1 R/R AML from a phase 1 trial. Receptor tyrosine kinase (RTK) pathway mutations were associated with primary resistance to ivosidenib. Multiple mechanisms contributed to acquired resistance, particularly outgrowth of RTK pathway mutations and 2-HG-restoring mutations (second-site IDH1 mutations, IDH2 mutations). Observation of multiple concurrent mechanisms in individual patients underscores the complex biology of resistance and has important implications for rational combination therapy design. This trial was registered at www.clinicaltrials.gov as #NCT02074839.



Authors

Choe, S., Wang, H., DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Watts, J.M., Pollyea, D.A., Fathi, A.T., Tallman, M.S., Kantarjian, H.M., Stone, R.M., Quek, L., Konteatis, Z., Dang, L., Nicolay, B., Nejad, P., Liu, G., Zhang, V., Liu, H., Goldwasser, M., Liu, W., Marks, K., Bowden, C., Biller, S.A., Attar, E.C., Wu, B.



VIEW

publication
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Taylor, J.
Blood (2020)
publication
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Maia, C.
Blood (2020)
publication
Distinct genetic pathways define pre-leukemic and compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Kennedy, A. L.
BioRxiv (2020)
publication
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo, C.D.
Blood (2020)
REQUEST QUOTE